The Series A round, which was led by RA Capital, will help fund the development of two genetic medicines designed to treat an ...
An early data check showed the shot didn’t delay tumor progression in a form of head and neck cancer, though BioNTech is ...
Yet one factor remains consistently underestimated: physical connectivity or fluid management. The tubing, connectors, ...
The offering will support a trio of medicines in or nearing clinical testing, as well as earlier research into RNAi ...
A revamped regulatory framework may give investors less of a “guessing game” as they weigh chances for drug approvals, one ...
The latest installment in BioPharma Dive’s data visualization-focused series includes a look at Moderna’s meteoric rise in 2026 and a sudden deal surge from Roche.
In a first, a subcutaneously administered RNA interference medicine crossed into the brain and plummeted levels of a protein ...
Wall Street analysts believe Verastem’s drug to now be “competitive” in what’s quickly become one of the most active and ...
One lawyer involved noted how it's yet another example of Paragon and key investor Fairmount — which have helped transform ...
Prosecutors say the company filled unnecessary prescriptions that fueled the opioid epidemic. A spokesperson for CVS said the company admitted to no wrongdoing and “strongly disagreed” with the case’s ...
A 6% sell-off in J&J shares was viewed by one analyst as emblematic of broader market volatility. Elsewhere, Gilead is ...
An alliance with Rona Therapeutics adds to a particularly active stretch for Roche and makes the company the latest to bet on ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results